| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ceramides | 40 | 2018 | 578 | 2.810 |
Why?
|
| Antineoplastic Agents | 14 | 2020 | 1070 | 1.360 |
Why?
|
| Photochemotherapy | 4 | 2022 | 59 | 1.140 |
Why?
|
| Enzyme Inhibitors | 8 | 2020 | 659 | 1.010 |
Why?
|
| Acid Ceramidase | 9 | 2020 | 85 | 0.980 |
Why?
|
| Ceramidases | 8 | 2020 | 47 | 0.970 |
Why?
|
| Propanolamines | 7 | 2017 | 70 | 0.880 |
Why?
|
| Acetates | 1 | 2020 | 74 | 0.710 |
Why?
|
| Hyperthermia, Induced | 1 | 2020 | 53 | 0.700 |
Why?
|
| Amines | 1 | 2020 | 98 | 0.690 |
Why?
|
| Sphingolipids | 11 | 2020 | 337 | 0.600 |
Why?
|
| Amides | 7 | 2014 | 86 | 0.590 |
Why?
|
| Sphingosine | 10 | 2017 | 315 | 0.560 |
Why?
|
| Apoptosis | 13 | 2020 | 1641 | 0.550 |
Why?
|
| Cell Line, Tumor | 22 | 2020 | 1851 | 0.460 |
Why?
|
| Myristates | 3 | 2008 | 21 | 0.450 |
Why?
|
| Cell Membrane | 6 | 2018 | 525 | 0.450 |
Why?
|
| Alkaline Ceramidase | 7 | 2010 | 35 | 0.390 |
Why?
|
| Amidohydrolases | 6 | 2007 | 60 | 0.390 |
Why?
|
| Pyridinium Compounds | 5 | 2013 | 40 | 0.390 |
Why?
|
| Drug Screening Assays, Antitumor | 4 | 2020 | 111 | 0.340 |
Why?
|
| Mitochondria | 6 | 2016 | 643 | 0.330 |
Why?
|
| Chromatography, High Pressure Liquid | 8 | 2016 | 381 | 0.320 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2019 | 346 | 0.290 |
Why?
|
| Cell Death | 6 | 2018 | 329 | 0.290 |
Why?
|
| Animals | 28 | 2022 | 20881 | 0.270 |
Why?
|
| Nitrobenzenes | 2 | 2017 | 13 | 0.270 |
Why?
|
| Protein Phosphatase 2 | 2 | 2019 | 67 | 0.270 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 2 | 2018 | 30 | 0.270 |
Why?
|
| Prodrugs | 2 | 2017 | 54 | 0.260 |
Why?
|
| Mitochondrial Membranes | 4 | 2015 | 45 | 0.260 |
Why?
|
| Tandem Mass Spectrometry | 5 | 2016 | 139 | 0.240 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 8 | 2010 | 67 | 0.240 |
Why?
|
| Cell Proliferation | 5 | 2020 | 1174 | 0.240 |
Why?
|
| Galactosylgalactosylglucosylceramidase | 4 | 2008 | 39 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2017 | 629 | 0.240 |
Why?
|
| Humans | 51 | 2022 | 68618 | 0.230 |
Why?
|
| Mice | 12 | 2022 | 8474 | 0.230 |
Why?
|
| Stereoisomerism | 6 | 2010 | 169 | 0.220 |
Why?
|
| RNA, Small Interfering | 7 | 2016 | 434 | 0.220 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2017 | 284 | 0.220 |
Why?
|
| Tumor Cells, Cultured | 5 | 2020 | 852 | 0.210 |
Why?
|
| Cell Nucleus | 3 | 2018 | 305 | 0.210 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 3 | 2017 | 201 | 0.210 |
Why?
|
| Inflammasomes | 1 | 2022 | 39 | 0.210 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2022 | 21 | 0.200 |
Why?
|
| Ion Channels | 2 | 2012 | 72 | 0.200 |
Why?
|
| Fingolimod Hydrochloride | 2 | 2019 | 24 | 0.190 |
Why?
|
| Radiation Tolerance | 1 | 2020 | 30 | 0.190 |
Why?
|
| Structure-Activity Relationship | 4 | 2017 | 420 | 0.190 |
Why?
|
| Golgi Apparatus | 5 | 2010 | 75 | 0.180 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2020 | 231 | 0.180 |
Why?
|
| Neoplasms | 4 | 2022 | 1667 | 0.180 |
Why?
|
| Oxidative Stress | 3 | 2018 | 718 | 0.180 |
Why?
|
| Arthritis, Experimental | 1 | 2020 | 38 | 0.180 |
Why?
|
| Rectal Neoplasms | 1 | 2020 | 75 | 0.180 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2020 | 77 | 0.180 |
Why?
|
| Necrosis | 2 | 2018 | 239 | 0.180 |
Why?
|
| Antigen Presentation | 1 | 2020 | 76 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2012 | 174 | 0.170 |
Why?
|
| HeLa Cells | 8 | 2018 | 237 | 0.170 |
Why?
|
| Autophagy | 2 | 2012 | 208 | 0.170 |
Why?
|
| Lung Neoplasms | 3 | 2018 | 1173 | 0.170 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2019 | 33 | 0.160 |
Why?
|
| Melanoma | 1 | 2022 | 335 | 0.160 |
Why?
|
| Multiple Sclerosis | 1 | 2020 | 132 | 0.160 |
Why?
|
| Molecular Motor Proteins | 1 | 2018 | 14 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 186 | 0.160 |
Why?
|
| Myosin Heavy Chains | 1 | 2018 | 49 | 0.160 |
Why?
|
| A549 Cells | 4 | 2019 | 50 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2017 | 626 | 0.160 |
Why?
|
| Substrate Specificity | 9 | 2011 | 234 | 0.150 |
Why?
|
| Prostatic Neoplasms | 3 | 2017 | 778 | 0.150 |
Why?
|
| Benzimidazoles | 2 | 2016 | 128 | 0.150 |
Why?
|
| Myristic Acid | 1 | 2017 | 6 | 0.150 |
Why?
|
| Phosphotransferases | 1 | 2017 | 16 | 0.150 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2017 | 26 | 0.150 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2017 | 13 | 0.150 |
Why?
|
| Mitochondria, Heart | 1 | 2018 | 53 | 0.150 |
Why?
|
| Acyltransferases | 1 | 2017 | 40 | 0.150 |
Why?
|
| Molecular Structure | 5 | 2015 | 397 | 0.150 |
Why?
|
| Cell Cycle | 4 | 2007 | 312 | 0.150 |
Why?
|
| Mitochondria, Liver | 3 | 2015 | 148 | 0.150 |
Why?
|
| Guanidines | 1 | 2017 | 32 | 0.150 |
Why?
|
| Stress, Physiological | 1 | 2018 | 215 | 0.140 |
Why?
|
| Sphingosine N-Acyltransferase | 1 | 2017 | 62 | 0.140 |
Why?
|
| Dextran Sulfate | 1 | 2017 | 88 | 0.140 |
Why?
|
| Cations | 5 | 2011 | 51 | 0.140 |
Why?
|
| Protein Binding | 7 | 2019 | 1027 | 0.140 |
Why?
|
| Oligodendroglioma | 1 | 2016 | 18 | 0.140 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2016 | 21 | 0.140 |
Why?
|
| Cell Division | 6 | 2010 | 541 | 0.140 |
Why?
|
| Cisplatin | 1 | 2017 | 192 | 0.140 |
Why?
|
| Cancer Vaccines | 1 | 2016 | 61 | 0.130 |
Why?
|
| Models, Molecular | 3 | 2012 | 546 | 0.130 |
Why?
|
| Piperidines | 1 | 2016 | 123 | 0.130 |
Why?
|
| Caspases | 4 | 2012 | 194 | 0.130 |
Why?
|
| Colitis | 1 | 2017 | 156 | 0.130 |
Why?
|
| Interferon-gamma | 1 | 2016 | 241 | 0.130 |
Why?
|
| Lysophospholipids | 3 | 2006 | 209 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 116 | 0.130 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2012 | 111 | 0.130 |
Why?
|
| Myocytes, Cardiac | 1 | 2018 | 442 | 0.120 |
Why?
|
| Blotting, Western | 7 | 2012 | 954 | 0.120 |
Why?
|
| Rats | 9 | 2015 | 5300 | 0.120 |
Why?
|
| Integrin beta1 | 3 | 2010 | 48 | 0.120 |
Why?
|
| Phosphorylation | 5 | 2017 | 1200 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 332 | 0.120 |
Why?
|
| Drug Design | 1 | 2014 | 107 | 0.120 |
Why?
|
| Mice, SCID | 4 | 2017 | 238 | 0.110 |
Why?
|
| Neutral Ceramidase | 2 | 2011 | 27 | 0.110 |
Why?
|
| Cell Line | 4 | 2020 | 1752 | 0.110 |
Why?
|
| Mutation | 2 | 2016 | 1213 | 0.110 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 1536 | 0.110 |
Why?
|
| Histone Chaperones | 1 | 2012 | 11 | 0.110 |
Why?
|
| Membrane Proteins | 1 | 2017 | 617 | 0.110 |
Why?
|
| Propylene Glycols | 1 | 2012 | 16 | 0.110 |
Why?
|
| Fenretinide | 2 | 2010 | 26 | 0.110 |
Why?
|
| Proteome | 1 | 2013 | 87 | 0.110 |
Why?
|
| Phagosomes | 1 | 2012 | 19 | 0.110 |
Why?
|
| Endoplasmic Reticulum | 4 | 2010 | 148 | 0.100 |
Why?
|
| Insulin-Secreting Cells | 1 | 2012 | 41 | 0.100 |
Why?
|
| Neurilemmoma | 1 | 2012 | 26 | 0.100 |
Why?
|
| NADPH Oxidases | 1 | 2012 | 80 | 0.100 |
Why?
|
| Cell Survival | 4 | 2020 | 901 | 0.100 |
Why?
|
| Group IV Phospholipases A2 | 2 | 2008 | 7 | 0.100 |
Why?
|
| Enzyme Activation | 6 | 2012 | 791 | 0.100 |
Why?
|
| Interferon Regulatory Factors | 1 | 2011 | 24 | 0.100 |
Why?
|
| Oxidoreductases | 2 | 2013 | 117 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2016 | 2689 | 0.100 |
Why?
|
| Keratinocytes | 2 | 2010 | 68 | 0.090 |
Why?
|
| Combinatorial Chemistry Techniques | 2 | 2007 | 25 | 0.090 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 63 | 0.090 |
Why?
|
| Growth Inhibitors | 1 | 2010 | 33 | 0.090 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2011 | 85 | 0.090 |
Why?
|
| Mass Spectrometry | 3 | 2007 | 284 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 370 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 2 | 2006 | 561 | 0.090 |
Why?
|
| Time Factors | 5 | 2010 | 4655 | 0.090 |
Why?
|
| Cytochromes c | 4 | 2012 | 75 | 0.080 |
Why?
|
| Telomerase | 3 | 2005 | 85 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 332 | 0.080 |
Why?
|
| Helplessness, Learned | 1 | 2008 | 9 | 0.080 |
Why?
|
| Proteins | 1 | 2012 | 474 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2012 | 753 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2015 | 2083 | 0.070 |
Why?
|
| Calcium | 2 | 2010 | 929 | 0.070 |
Why?
|
| Up-Regulation | 4 | 2013 | 682 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2010 | 384 | 0.070 |
Why?
|
| Capsid Proteins | 1 | 2006 | 27 | 0.070 |
Why?
|
| Solubility | 1 | 2006 | 134 | 0.070 |
Why?
|
| Brain | 2 | 2011 | 2176 | 0.070 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2006 | 8 | 0.070 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2006 | 19 | 0.070 |
Why?
|
| Drug Synergism | 3 | 2017 | 260 | 0.070 |
Why?
|
| Neuroblastoma | 1 | 2007 | 109 | 0.070 |
Why?
|
| Genetic Therapy | 1 | 2008 | 291 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2012 | 304 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2006 | 90 | 0.060 |
Why?
|
| Phosphatidylcholines | 1 | 2005 | 38 | 0.060 |
Why?
|
| Phospholipases A | 1 | 2005 | 41 | 0.060 |
Why?
|
| Hippocampus | 1 | 2008 | 471 | 0.060 |
Why?
|
| Lysosomes | 3 | 2014 | 136 | 0.060 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenase (NADP+)(Phosphorylating) | 1 | 2003 | 4 | 0.060 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2003 | 67 | 0.060 |
Why?
|
| Microscopy, Confocal | 3 | 2012 | 337 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2010 | 282 | 0.050 |
Why?
|
| Cell Extracts | 1 | 2003 | 21 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2017 | 2673 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 2550 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 468 | 0.050 |
Why?
|
| Down-Regulation | 3 | 2010 | 447 | 0.050 |
Why?
|
| Membrane Potential, Mitochondrial | 2 | 2012 | 93 | 0.050 |
Why?
|
| Hydrolysis | 3 | 2010 | 144 | 0.050 |
Why?
|
| Microscopy, Electron | 3 | 2008 | 351 | 0.050 |
Why?
|
| Protein Transport | 3 | 2008 | 280 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2011 | 618 | 0.050 |
Why?
|
| Male | 8 | 2020 | 37321 | 0.050 |
Why?
|
| Depression | 1 | 2008 | 943 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2010 | 489 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2007 | 710 | 0.050 |
Why?
|
| Organoids | 1 | 2020 | 42 | 0.050 |
Why?
|
| X-Rays | 1 | 2020 | 56 | 0.050 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 41 | 0.050 |
Why?
|
| HLA-DR4 Antigen | 1 | 2020 | 11 | 0.050 |
Why?
|
| Models, Biological | 2 | 2020 | 981 | 0.050 |
Why?
|
| Cathepsins | 1 | 2020 | 37 | 0.050 |
Why?
|
| Gene Editing | 1 | 2020 | 33 | 0.050 |
Why?
|
| Mice, Inbred DBA | 1 | 2020 | 120 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2020 | 50 | 0.050 |
Why?
|
| Chromatography, Liquid | 2 | 2012 | 120 | 0.040 |
Why?
|
| Fas Ligand Protein | 2 | 2011 | 64 | 0.040 |
Why?
|
| Lipids | 2 | 2012 | 298 | 0.040 |
Why?
|
| Deoxycytidine | 2 | 2012 | 83 | 0.040 |
Why?
|
| Reference Standards | 2 | 2010 | 115 | 0.040 |
Why?
|
| Dimerization | 1 | 2019 | 99 | 0.040 |
Why?
|
| Caspase 3 | 2 | 2012 | 233 | 0.040 |
Why?
|
| Transfection | 3 | 2006 | 782 | 0.040 |
Why?
|
| Oogenesis | 1 | 2018 | 10 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 24 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2002 | 475 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 226 | 0.040 |
Why?
|
| Permeability | 2 | 2012 | 131 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2018 | 55 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2018 | 63 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2018 | 68 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2018 | 78 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 329 | 0.040 |
Why?
|
| Ovary | 1 | 2018 | 99 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 89 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2018 | 80 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 597 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2006 | 1083 | 0.040 |
Why?
|
| Calibration | 2 | 2009 | 73 | 0.040 |
Why?
|
| Desipramine | 2 | 2008 | 47 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 2011 | 532 | 0.040 |
Why?
|
| Ligands | 1 | 2018 | 317 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 137 | 0.040 |
Why?
|
| Chemokine CXCL2 | 1 | 2017 | 13 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2006 | 1447 | 0.040 |
Why?
|
| Chemokine CXCL1 | 1 | 2017 | 21 | 0.040 |
Why?
|
| Heterografts | 1 | 2017 | 70 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 160 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2017 | 62 | 0.040 |
Why?
|
| Reactive Oxygen Species | 2 | 2012 | 499 | 0.040 |
Why?
|
| Isoenzymes | 2 | 2011 | 308 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2017 | 112 | 0.040 |
Why?
|
| Dynamins | 1 | 2016 | 14 | 0.040 |
Why?
|
| Macrophages | 1 | 2020 | 647 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 1293 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2016 | 46 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2017 | 326 | 0.030 |
Why?
|
| Extracellular Vesicles | 1 | 2016 | 21 | 0.030 |
Why?
|
| Membrane Potentials | 2 | 2007 | 200 | 0.030 |
Why?
|
| DNA Primers | 2 | 2007 | 302 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 194 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 138 | 0.030 |
Why?
|
| Exosomes | 1 | 2016 | 44 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2016 | 35 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2016 | 93 | 0.030 |
Why?
|
| Oligodendroglia | 1 | 2016 | 107 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 113 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2016 | 114 | 0.030 |
Why?
|
| Cell Adhesion | 2 | 2008 | 324 | 0.030 |
Why?
|
| RNA Interference | 2 | 2007 | 266 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1330 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 126 | 0.030 |
Why?
|
| Female | 4 | 2020 | 38074 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2015 | 137 | 0.030 |
Why?
|
| Sphingomyelin Phosphodiesterase | 2 | 2007 | 183 | 0.030 |
Why?
|
| Esters | 1 | 2014 | 22 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 80 | 0.030 |
Why?
|
| Plasmids | 2 | 2006 | 258 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2010 | 1664 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 1038 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 951 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2017 | 7029 | 0.030 |
Why?
|
| Base Sequence | 2 | 2007 | 1015 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 129 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 947 | 0.030 |
Why?
|
| Carbocyanines | 1 | 2012 | 13 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2012 | 16 | 0.030 |
Why?
|
| Bromides | 1 | 2012 | 17 | 0.030 |
Why?
|
| Nitrophenols | 1 | 2012 | 14 | 0.030 |
Why?
|
| Spectrum Analysis | 1 | 2012 | 81 | 0.030 |
Why?
|
| Coloring Agents | 1 | 2012 | 66 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2012 | 37 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2013 | 250 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2012 | 77 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2012 | 52 | 0.030 |
Why?
|
| Glioma | 1 | 2013 | 140 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 247 | 0.030 |
Why?
|
| Horses | 1 | 2012 | 20 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 196 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2012 | 294 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 258 | 0.020 |
Why?
|
| Biphenyl Compounds | 1 | 2012 | 184 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2006 | 1745 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 331 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2012 | 141 | 0.020 |
Why?
|
| K562 Cells | 1 | 2011 | 44 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2011 | 42 | 0.020 |
Why?
|
| Peptides | 2 | 2005 | 455 | 0.020 |
Why?
|
| Binding Sites | 2 | 2003 | 631 | 0.020 |
Why?
|
| Reducing Agents | 1 | 2011 | 5 | 0.020 |
Why?
|
| Sepharose | 1 | 2011 | 18 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 2791 | 0.020 |
Why?
|
| Glycoside Hydrolases | 1 | 2011 | 25 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 4848 | 0.020 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2010 | 24 | 0.020 |
Why?
|
| Piperazines | 1 | 2012 | 206 | 0.020 |
Why?
|
| Catalysis | 1 | 2011 | 123 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 567 | 0.020 |
Why?
|
| Phospholipids | 1 | 2011 | 108 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2011 | 57 | 0.020 |
Why?
|
| Lysosome-Associated Membrane Glycoproteins | 1 | 2010 | 6 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 306 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2010 | 35 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2010 | 54 | 0.020 |
Why?
|
| Cytosol | 1 | 2010 | 123 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2011 | 193 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2010 | 97 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 492 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 322 | 0.020 |
Why?
|
| Alkanes | 1 | 2008 | 10 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 562 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2009 | 73 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 615 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 700 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2012 | 706 | 0.020 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2008 | 45 | 0.020 |
Why?
|
| Tretinoin | 1 | 2008 | 92 | 0.020 |
Why?
|
| Kinetics | 1 | 2010 | 1047 | 0.020 |
Why?
|
| Chicken anemia virus | 1 | 2008 | 5 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2010 | 317 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2007 | 84 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 63 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 95 | 0.020 |
Why?
|
| Random Allocation | 1 | 2008 | 442 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2007 | 92 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2008 | 312 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2011 | 1692 | 0.020 |
Why?
|
| Endosomes | 1 | 2006 | 45 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2006 | 31 | 0.020 |
Why?
|
| Carbon Isotopes | 1 | 2006 | 54 | 0.020 |
Why?
|
| Automation | 1 | 2006 | 45 | 0.020 |
Why?
|
| Inactivation, Metabolic | 1 | 2006 | 28 | 0.020 |
Why?
|
| Thioredoxin Reductase 1 | 1 | 2006 | 3 | 0.020 |
Why?
|
| Thioredoxin-Disulfide Reductase | 1 | 2006 | 5 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2006 | 191 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2006 | 41 | 0.020 |
Why?
|
| Acylation | 1 | 2006 | 22 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 1040 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2006 | 82 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2006 | 295 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2006 | 282 | 0.020 |
Why?
|
| Solvents | 1 | 2006 | 109 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2010 | 375 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2006 | 304 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2006 | 141 | 0.020 |
Why?
|
| Phospholipases A2 | 1 | 2005 | 32 | 0.020 |
Why?
|
| Insecta | 1 | 2005 | 11 | 0.020 |
Why?
|
| Anoikis | 1 | 2005 | 3 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2008 | 493 | 0.020 |
Why?
|
| Brefeldin A | 1 | 2005 | 11 | 0.020 |
Why?
|
| Pseudopodia | 1 | 2005 | 16 | 0.020 |
Why?
|
| Biotinylation | 1 | 2005 | 27 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 376 | 0.020 |
Why?
|
| Allosteric Regulation | 1 | 2005 | 58 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2006 | 231 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2005 | 222 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2005 | 84 | 0.020 |
Why?
|
| Cell Separation | 1 | 2005 | 132 | 0.020 |
Why?
|
| Aged | 1 | 2020 | 14862 | 0.020 |
Why?
|
| Microtubules | 1 | 2005 | 104 | 0.020 |
Why?
|
| Glycosylation | 1 | 2005 | 185 | 0.010 |
Why?
|
| Holoenzymes | 1 | 2003 | 7 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2006 | 483 | 0.010 |
Why?
|
| Silver Staining | 1 | 2003 | 11 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2003 | 50 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 88 | 0.010 |
Why?
|
| Gene Expression | 1 | 2006 | 770 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2006 | 299 | 0.010 |
Why?
|
| Alkalies | 1 | 2003 | 6 | 0.010 |
Why?
|
| Actins | 1 | 2005 | 249 | 0.010 |
Why?
|
| Telomere | 1 | 2003 | 59 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 144 | 0.010 |
Why?
|
| Chromatin | 1 | 2003 | 76 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2003 | 155 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2003 | 130 | 0.010 |
Why?
|
| COS Cells | 1 | 2003 | 155 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2007 | 1034 | 0.010 |
Why?
|
| Diacylglycerol Kinase | 1 | 2003 | 8 | 0.010 |
Why?
|
| Atmospheric Pressure | 1 | 2003 | 8 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2003 | 246 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 261 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 357 | 0.010 |
Why?
|
| Middle Aged | 1 | 2020 | 21147 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2008 | 824 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 1753 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2002 | 165 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2002 | 231 | 0.010 |
Why?
|
| Skin | 1 | 2003 | 451 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 1118 | 0.010 |
Why?
|